We acquired the approximately 95‑acre industrial property in the city of Saarlouis at the end of 2024. Our decision for this location followed careful strategic investment considerations and is supported by significant regional advantages. In the long term, we see the potential to create up to 2,000 jobs at this site. The European Commission has approved up to €47 million in state aid for this major project.
With the construction of our new production facility in Germany, we continue on our path to sustainable growth. Long-term success derives from striking the right balance between stability and expansion. With our investments in the state of Saarland, only a five-hour drive away from our headquarters in Ravensburg, we are strengthening our commitment to Germany’s economic landscape while reaffirming our engagement as a strategic partner to the global pharmaceutical market.
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family
In parallel, we have recently begun construction on a new clinical production site in Des Plaines, Illinois, USA. This new aseptic manufacturing facility underscores our commitment to providing high‑quality services and drug products during early clinical development.
For more than 75 years, we have been dedicated to quality, innovation, and responsibility in the production of sterile pharmaceuticals, helping to improve the lives of patients around the world. To meet growing customer demand and evolving market requirements, we are investing in our existing sites in Germany, Austria, and the United States. With our newly planned commercial site, we will significantly expand our production capacity.
